Amgen Inc (AMGN)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 43% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+50% over the past year+3
- 52-week positionPressing 52-week highs+30
- QualityStrong net margin (23%)+7
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is product (clinical data), as the ESMO lung cancer survival results and related coverage center on pipeline readouts rather than earnings or M&A. Continuation likelihood over the next few weeks is moderate (~40–50%), since positive data can sustain interest but the effect often fades absent a regulatory or commercial follow-through. Informational only — not financial advice.
- ESMO26: Key data breathing new life into the lung cancer fieldYahoo · 2026-10-26
- Can Incyte Stock Hit $170?Yahoo · 2026-10-26
- Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung CancerBenzinga · 2026-10-26
- Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?Yahoo · 2026-10-25
- Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress TranscriptSeekingAlpha · 2026-10-24
Any AI summary is an interpretation of public news, not advice or a price target.